Literature DB >> 28476219

Dose to heart substructures is associated with non-cancer death after SBRT in stage I-II NSCLC patients.

Barbara Stam1, Heike Peulen1, Matthias Guckenberger2, Frederick Mantel3, Andrew Hope4, Maria Werner-Wasik5, Jose Belderbos1, Inga Grills6, Nicolette O'Connell7, Jan-Jakob Sonke8.   

Abstract

BACKGROUND AND
PURPOSE: To investigate potential associations between dose to heart (sub)structures and non-cancer death, in early stage non-small cell lung cancer (NSCLC) patients treated with stereotactic body radiation therapy (SBRT).
METHODS: 803 patients with early stage NSCLC received SBRT with predominant schedules of 3×18Gy (59%) or 4×12Gy (19%). All patients were registered to an average anatomy, their planned dose deformed accordingly, and dosimetric parameters for heart substructures were obtained. Multivariate Cox regression and a sensitivity analysis were used to identify doses to heart substructures or heart region with a significant association with non-cancer death respectively.
RESULTS: Median follow-up was 34.8months. Two year Kaplan-Meier overall survival rate was 67%. Of the deceased patients, 26.8% died of cancer. Multivariate analysis showed that the maximum dose on the left atrium (median 6.5Gy EQD2, range=0.009-197, HR=1.005, p-value=0.035), and the dose to 90% of the superior vena cava (median 0.59Gy EQD2, range=0.003-70, HR=1.025, p-value=0.008) were significantly associated with non-cancer death. Sensitivity analysis identified the upper region of the heart (atria+vessels) to be significantly associated with non-cancer death.
CONCLUSIONS: Doses to mainly the upper region of the heart were significantly associated with non-cancer death. Consequently, dose sparing in particular of the upper region of the heart could potentially improve outcome, and should be further studied.
Copyright © 2017 Elsevier B.V. All rights reserved.

Entities:  

Keywords:  Heart toxicity; Lung cancer; SBRT

Mesh:

Year:  2017        PMID: 28476219     DOI: 10.1016/j.radonc.2017.04.017

Source DB:  PubMed          Journal:  Radiother Oncol        ISSN: 0167-8140            Impact factor:   6.280


  36 in total

1.  Evaluating Positron Emission Tomography-Based Functional Imaging Changes in the Heart After Chemo-Radiation for Patients With Lung Cancer.

Authors:  Yevgeniy Vinogradskiy; Quentin Diot; Bernard Jones; Richard Castillo; Edward Castillo; Jennifer Kwak; Daniel Bowles; Inga Grills; Nicholas Myziuk; Thomas Guerrero; Craig Stevens; Tracey Schefter; Laurie E Gaspar; Brian Kavanagh; Moyed Miften; Chad Rusthoven
Journal:  Int J Radiat Oncol Biol Phys       Date:  2020-01-23       Impact factor: 7.038

2.  Effect of accurate heart delineation on cardiac dose during the CONVERT trial.

Authors:  Nicki Groom; Elena Wilson; Corinne Faivre-Finn
Journal:  Br J Radiol       Date:  2017-03-31       Impact factor: 3.039

3.  Detecting spatial susceptibility to cardiac toxicity of radiation therapy for lung cancer.

Authors:  Xiaonan Liu; Mirek Fatyga; Steven E Schild; Jing Li
Journal:  IISE Trans Healthc Syst Eng       Date:  2020-07-22

Review 4.  Mechanisms and Review of Clinical Evidence of Variations in Relative Biological Effectiveness in Proton Therapy.

Authors:  Harald Paganetti
Journal:  Int J Radiat Oncol Biol Phys       Date:  2021-08-15       Impact factor: 8.013

5.  Mutual enhancing learning-based automatic segmentation of CT cardiac substructure.

Authors:  Shadab Momin; Yang Lei; Neal S McCall; Jiahan Zhang; Justin Roper; Joseph Harms; Sibo Tian; Michael S Lloyd; Tian Liu; Jeffrey D Bradley; Kristin Higgins; Xiaofeng Yang
Journal:  Phys Med Biol       Date:  2022-05-11       Impact factor: 4.174

6.  Heart dosimetric analysis of three types of cardiac toxicity in patients treated on dose-escalation trials for Stage III non-small-cell lung cancer.

Authors:  Kyle Wang; Kevin A Pearlstein; Nicholas D Patchett; Allison M Deal; Panayiotis Mavroidis; Brian C Jensen; Matthew B Lipner; Timothy M Zagar; Yue Wang; Carrie B Lee; Michael J Eblan; Julian G Rosenman; Mark A Socinski; Thomas E Stinchcombe; Lawrence B Marks
Journal:  Radiother Oncol       Date:  2017-10-16       Impact factor: 6.280

7.  Cardiac radiation dose distribution, cardiac events and mortality in early-stage lung cancer treated with stereotactic body radiation therapy (SBRT).

Authors:  Leonid B Reshko; Noah S Kalman; Geoffrey D Hugo; Elisabeth Weiss
Journal:  J Thorac Dis       Date:  2018-04       Impact factor: 2.895

8.  Using Auto-Segmentation to Reduce Contouring and Dose Inconsistency in Clinical Trials: The Simulated Impact on RTOG 0617.

Authors:  Maria Thor; Aditya Apte; Rabia Haq; Aditi Iyer; Eve LoCastro; Joseph O Deasy
Journal:  Int J Radiat Oncol Biol Phys       Date:  2020-11-13       Impact factor: 7.038

9.  Probing thoracic dose patterns associated to pericardial effusion and mortality in patients treated with photons and protons for locally advanced non-small-cell lung cancer.

Authors:  Laura Cella; Serena Monti; Ting Xu; Raffaele Liuzzi; Arnaldo Stanzione; Marco Durante; Radhe Mohan; Zhongxing Liao; Giuseppe Palma
Journal:  Radiother Oncol       Date:  2021-05-09       Impact factor: 6.901

10.  Risk of Cardiovascular Toxicity According to Tumor Laterality Among Older Patients With Early Stage Non-small Cell Lung Cancer Treated With Radiation Therapy.

Authors:  Benjamin Y Liu; Sadiq Rehmani; Minal S Kale; Deborah Marshall; Kenneth E Rosenzweig; Chung Yin Kong; Juan Wisnivesky; Keith Sigel
Journal:  Chest       Date:  2022-01-19       Impact factor: 10.262

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.